Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study

TY - JOUR

T1 - Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study

AU - Mussetti, A

AU - Rius-Sansalvador, B

AU - Moreno, V

AU - Peczynski, C

AU - Polge, E

AU - Galimard, J E

AU - Kröger, N

AU - Blaise, D

AU - Peffault de Latour, R

AU - Kulagin, A

AU - Mousavi, A

AU - Stelljes, M

AU - Hamladji, R M

AU - Middeke, J M

AU - Salmenniemi, U

AU - Sengeloev, H

AU - Forcade, E

AU - Platzbecker, U

AU - Reményi, P

AU - Angelucci, E

AU - Chevallier, P

AU - Yakoub-Agha, I

AU - Craddock, C

AU - Ciceri, F

AU - Schroeder, T

AU - Aljurf, M

AU - Ch, Koenecke

AU - Moiseev, I

AU - Penack, O

AU - Schoemans, H

AU - Mohty, M

AU - Glass, B

AU - Sureda, A

AU - Basak, G

AU - Peric, Z

N1 - © 2023. The Author(s), under exclusive licence to Springer Nature Limited.

PY - 2024/2

Y1 - 2024/2

N2 - Allogeneic haematopoietic cell transplantation (alloHCT) has curative potential counterbalanced by its toxicity. Prognostic scores fail to include current era patients and alternative donors. We examined adult patients from the EBMT registry who underwent alloHCT between 2010 and 2019 for oncohaematological disease. Our primary objective was to develop a new prognostic score for overall mortality (OM), with a secondary objective of predicting non-relapse mortality (NRM) using the OM score. AI techniques were employed. The model for OM was trained, optimized, and validated using 70%, 15%, and 15% of the data set, respectively. The top models, "gradient boosting" for OM (AUC = 0.64) and "elasticnet" for NRM (AUC = 0.62), were selected. The analysis included 33,927 patients. In the final prognostic model, patients with the lowest score had a 2-year OM and NRM of 18 and 13%, respectively, while those with the highest score had a 2-year OM and NRM of 82 and 93%, respectively. The results were consistent in the subset of the haploidentical cohort (n = 4386). Our score effectively stratifies the risk of OM and NRM in the current era but do not significantly improve mortality prediction. Future prognostic scores can benefit from identifying biological or dynamic markers post alloHCT.

AB - Allogeneic haematopoietic cell transplantation (alloHCT) has curative potential counterbalanced by its toxicity. Prognostic scores fail to include current era patients and alternative donors. We examined adult patients from the EBMT registry who underwent alloHCT between 2010 and 2019 for oncohaematological disease. Our primary objective was to develop a new prognostic score for overall mortality (OM), with a secondary objective of predicting non-relapse mortality (NRM) using the OM score. AI techniques were employed. The model for OM was trained, optimized, and validated using 70%, 15%, and 15% of the data set, respectively. The top models, "gradient boosting" for OM (AUC = 0.64) and "elasticnet" for NRM (AUC = 0.62), were selected. The analysis included 33,927 patients. In the final prognostic model, patients with the lowest score had a 2-year OM and NRM of 18 and 13%, respectively, while those with the highest score had a 2-year OM and NRM of 82 and 93%, respectively. The results were consistent in the subset of the haploidentical cohort (n = 4386). Our score effectively stratifies the risk of OM and NRM in the current era but do not significantly improve mortality prediction. Future prognostic scores can benefit from identifying biological or dynamic markers post alloHCT.

U2 - 10.1038/s41409-023-02147-5

DO - 10.1038/s41409-023-02147-5

M3 - SCORING: Journal article

C2 - 38007531

VL - 59

SP - 232

EP - 238

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 2

ER -